login
Password reminder
Cardiovascular News
Contact the editor Visit Cardiovascular News Twitter feed Visit Cardiovascular News Facebook page
 

St Jude Medical establishes Cardiovascular Division


Thursday, 16 Nov 2006 00:00

St Jude Medical is combining its Cardiac Surgery and Cardiology divisions to create a new Cardiovascular Division, effective 1st January 2007. The Cardiovascular Division will focus on developing and bringing to market medical device technology and services to help patients who suffer from vascular disease or structural heart defects. The Cardiovascular Division will incorporate the activities currently managed by the Cardiac Surgery Division and by the Cardiology Division. The company will continue to have specialised cardiac surgery and cardiology sales forces.

According to Daniel J Starks, chairman, president and CEO of St Jude Medical, the company's cardiology and cardiac surgery businesses will be stronger together than each business is separately. Moreover, he claimed that by streamlining the organisation, the company can boost operating efficiencies and ultimately use the associated savings to invest in research and development.

The new Cardiovascular Division will be led by George J Fazio, who has served as president of St Jude Medical's Cardiac Surgery Division since 2004. Prior to his current role, Fazio was appointed president of St Jude Medical Europe in 2001. His preceding roles included president, Health Care Services for St Jude Medical, and general manager for St Jude Medical's operations in Canada.

Paul R Buckman, currently president of St Jude Medical's Cardiology Division, will become corporate vice president of Business Development. Since joining St Jude Medical in 2004 in his current role, Buckman has overseen a significant expansion of the Cardiology Division's products and programmes. The company is also initiating several changes to enhance the efficiency and effectiveness of its sales and customer service operations in certain international geographies.

As a result of these restructuring plans, St Jude Medical expects to incur a pre-tax charge of US$25 million to US$35 million during the third quarter of 2006. "The creation of a new Cardiovascular Division, together with the expansion of our sales force and recent new product introductions, are part of our comprehensive program to position St Jude Medical to deliver a minimum 15% growth in 2007 and beyond," Starks concluded.



Most popular


Men believe “long working hours” stop women from being interventional cardiologists
Wednesday, 15 Jul 2015
According to a new survey published in EuroIntervention, men state that the long working hours and the need to be on call that is associated with being an interventional cardiologist are the key ... Men believe “long working hours” stop women from being interventional cardiologists

Merit Medical Systems launches the Prelude Snap splittable sheath introducer
Wednesday, 03 Jun 2015
Merit Medical Systems has launched the Prelude Snap splittable sheath introducer, the design of which is based directly on physician feedback. Merit Medical Systems launches the Prelude Snap splittable sheath introducer

Boston Scientific launches bioresorbable scaffold trial
Monday, 20 Jul 2015
Boston Scientific has initiated a study to evaluate its fully resorbable scaffold technology. FAST (Fully absorbable scaffold feasibility study) is a prospective, single-arm study designed to assess ... Boston Scientific launches bioresorbable scaffold trial

Features


Strut coverage: Optical coherence tomography and new stent technologies
Monday, 20 Jul 2015
Tim Kinnaird explores the risk of stent thrombosis with current technologies, how new technologies may be able to reduce this risk, and how OCT can help to assess this risk. Strut coverage: Optical coherence tomography and new stent technologies

The second generation of drug-eluting stents with biodegradable polymers may have potential advantages
Monday, 06 Jul 2015
Drug-eluting stents with biodegradable polymers have theoretical advantages over drug-eluting stents with permanent polymers—even second-generation drug-eluting stents. The second generation of drug-eluting stents with biodegradable polymers may have potential advantages

Profiles


Deepak L Bhatt
Tuesday, 09 Jun 2015
Deepak L Bhatt (Executive director of Interventional Cardiovascular Programs, Brigham and Women’s H... Deepak L Bhatt

Flavio Ribichini
Thursday, 05 Mar 2015
Flavio Ribichini speaks to Cardiovascular News about being involved in the first use of primary ... Flavio Ribichini

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions